Products
Enlyton is developing ATA-1 (an anti-TAG-72 humanized monoclonal antibody fragment coupled with I-124) as a cancer-specific targeting agent for PET/CT imaging.
Enlyton expects to enter clinical trials with ATA-1 in late 2012.
Enlyton is developing ATA-1 (an anti-TAG-72 humanized monoclonal antibody fragment coupled with I-124) as a cancer-specific targeting agent for PET/CT imaging.
Enlyton expects to enter clinical trials with ATA-1 in late 2012.
